Pill Identifier App

Generic Propecia Availability

Propecia is a brand name of finasteride, approved by the FDA in the following formulation(s):

PROPECIA (finasteride - tablet; oral)

  • Manufacturer: MERCK
    Approval date: December 19, 1997
    Strength(s): 1MG [RLD] [AB]

Has a generic version of Propecia been approved?

A generic version of Propecia has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Propecia and have been approved by the FDA:

finasteride tablet; oral

  • Manufacturer: DR REDDYS LABS INC
    Approval date: July 28, 2006
    Strength(s): 1MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Propecia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Method of treating androgenic alopecia with 5-.alpha. reductase inhibitors
    Patent 5,547,957
    Issued: August 20, 1996
    Inventor(s): Gormley; Glenn J. & Kaufman; Keith D. & Stoner; Elizabeth & Waldstreicher; Joanne
    Assignee(s): Merck & Co., Inc.
    The instant invention involves a method of treating and/or reversing androgenic alopecia and promoting hair growth, and methods of treating acne vulgaris, seborrhea, and female hirsutism, by administering to a patient in need of such treatment a 5.alpha.-reductase 2 inhibitor, such as finasteride, in a dosage amount under 5 mgs/day.
    Patent expiration dates:
    • October 15, 2013
      ✓ 
      Patent use: TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY
  • Methods of treating androgenic alopecia with finasteride [17.beta.-N-mono-substituted-carbamoyl-4-aza-5-.alpha.-androst-1-en-ones]
    Patent 5,571,817
    Issued: November 5, 1996
    Inventor(s): Rasmusson; Gary H. & Reynolds; Glenn F.
    Assignee(s): Merck & Co., Inc.
    17.beta.-N-monosubstituted-carbamoyl-4-5.alpha.-androst-1-en-3-ones of the formula ##STR1## wherein R.sup.1 is selected from hydrogen, methyl and ethyl and R.sup.2 is a branched chain alkyl of from 3-12 carbons, and R', R", R'" are hydrogen or methyl are active as testosterone 5.alpha.-reductase inhibitors and thus are useful topically for treatment of androgenic alopecia.
    Patent expiration dates:
    • November 5, 2013
      ✓ 
      Patent use: TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE
  • Finasteride processes
    Patent 5,886,184
    Issued: March 23, 1999
    Inventor(s): Dolling; Ulf H. & McCauley; James A. & Varsolona; Richard J.
    Assignee(s): Merck & Co., Inc.
    Disclosed is a new process for producing finasteride which involves reacting the magnesium halide salt of 17.beta.-carboalkoxy-4-aza-5.alpha.-androst-1-en-3-one with t-butylamino magnesium halide, present in at least a 2:1 molar ratio to the ester, formed from t-butyl amine and an aliphatic/aryl magnesium halide at ambient temperature in an inert organic solvent under an inert atmosphere followed by heating and recovering the product finasteride. Also disclosed are two polymorphic crystalline Forms I and II of finasteride, and methods of their production.
    Patent expiration dates:
    • November 19, 2012

See also...

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
Advertisement
Close

Recommended

(web4)